NATIONAL INSTITUTES OF HEALTH
National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS)
NIH NEWS RELEASE
FOR IMMEDIATE RELEASE
Wednesday, March 14, 2001
Contacts:
Kelli Carrington or Susan Bettendorf
Office of Communications and Public Liaison, NIAMS
(301) 496-8190
NEW RESEARCH REGISTRY TO EXAMINE RHEUMATOID ARTHRITIS IN
AFRICAN AMERICANS
Four major academic medical centers in the southeast United
States will soon be gathering data for investigators
interested in the genetics of rheumatoid arthritis (RA) in
African Americans, with support from the National Institute
of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
The Institute, a component of the National Institutes of
Health (NIH), has awarded a research contract for the
Consortium for the Longitudinal Evaluations of African
Americans with Early Rheumatoid Arthritis (CLEAR) Registry
to the University of Alabama at Birmingham (UAB). Other
participating centers are Emory University, the Medical
University of South Carolina and the University of North
Carolina.
The registry will provide clinical and x-ray data and DNA
to help scientists analyze genetic and nongenetic factors
that might predict disease course and outcomes of RA in
this population.
Certain genes that play a role in the
immune system are associated with a tendency to develop RA.
Some individuals without these genes may develop this
disease, while others who possess the genes never develop
RA. Scientists believe
that some environmental factors may
play a part, triggering the disease process in people whose
genetic makeup makes them susceptible to RA.
The investigators intend to register 600 participants.
Since there are currently no ongoing studies evaluating
early RA in African Americans, the investigators have
focused on this population.
African Americans are
underrepresented in most clinical studies, including
current observational studies of people with RA.
"Identifying any factor, genetic or otherwise, that may
predispose an individual to rheumatoid arthritis or provide
clues to an individual's disease outcome will greatly
improve our efforts to treat and ultimately prevent this
disease which affects so many people," said Stephen I.
Katz, M.D., Ph.D., NIAMS director.
"This registry of African Americans with early RA will
be
critical in identifying risk factors, including genetic and
environmental, that point to a more aggressive disease
process," said Larry Moreland, M.D., principal
investigator
of the CLEAR Registry.
"Ultimately, the ability to
identify patients very early in the disease process who
might have a worse long-term outcome will allow physicians
to provide better treatments for these patients."
Participating investigators are S. Louis Bridges, Jr.,
M.D., Ph.D., co-director of CLEAR at UAB; Doyt L. Conn,
M.D., and Janet McNicholl, M.D., at Emory University,
Atlanta, Ga.; Edwin Smith, M.D., and Gary Gilkeson, M.D.,
at the Medical University of South Carolina, Charleston;
and Beth Jonas, M.D., and Leigh Callahan, Ph.D., at the
University of North Carolina, Chapel Hill.
RA is an autoimmune disease, in which the body's immune
system attacks its own tissues. It occurs in all races and
ethnic groups, and affects about two to three times as many
women as men.
Scientists estimate that RA affects the
lives of one percent of the adult population in the United
States, although young adults and children can also be
affected. Symptoms
and severity vary greatly among
individuals, and may include inflammation, pain, swelling,
stiffness and progressive loss of function in the joints.
It may also cause fatigue, occasional fever and a general
sense of not feeling well.
In some cases, the internal
organs and systems can become involved and ultimately
damaged.
Patient enrollment for the registry is projected to begin
in late spring 2001. The project is funded under NIH
contract # N01-AR-0-2247.
The National Institute of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS) is a component of the National
Institutes of Health. The mission of the NIAMS is to
support research into the causes, treatment and prevention
of arthritis and musculoskeletal and skin diseases, the
training of basic and clinical scientists to carry out this
research, and the dissemination of information on research
progress in these diseases. For more information about
NIAMS, call our information clearinghouse at (301) 495-4484
or (877) 22-NIAMS (free call) or visit the NIAMS Web site
at http://www.nih.gov/niams.
To interview Dr. Larry Moreland, contact Joy Carter, Office
of Media Relations, University of Alabama at Birmingham, at
205-934-1676.
To enroll in the registry, contact one of the following
individuals who will direct you to the appropriate
representative in each participating state:
Tina Parkhill (205-934-9368; e-mail:
tina.parkhill@ccc.uab.edu) or
Fannie Johnson, R.N. (205-934-7427; e-mail:
fannie.johnson@ccc.uab.edu)
The Spain Rehabilitation Center
University of Alabama, Birmingham
Arthritis Center Clinical Intervention Program
SRC 068, ZIP 7201
1717 6th Avenue South
Birmingham, AL 35294
fax: 205-975-5554